CLNN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 7.83
- P/S (TTM)
- 361.59
- EV/EBITDA
- -1.13
Profitability & growth
- ROE (TTM)
- -1738.0%
- Operating margin
- -9734.0%
- Revenue growth YoY
- -15.4%
- Dividend yield
- —
- Beta
- 0.89
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Clene Inc.
Company profileClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
Classification
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 6550 SOUTH MILLROCK DRIVE, SALT LAKE CITY, UT
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer